Lilly GMP “Culture Change” Will Address Compliance Issues, Firm Tells FDA

Lilly is seeking to "affect cultural change" in its approach to GMP compliance, the company assured FDA in a response to the most recent FDA-483 manufacturing report for Forteo and Zyprexa IM